Claritas Acquires Qubiotech to Expand Quantitative PET Solutions
News related to:Claritas NucMed Technologies Ltd · 3 min read
LONDON, Oct. 22, 2026 /CourierPR/ -- Claritas NucMed Technologies Ltd., a subsidiary of Claritas HealthTech Ltd., has entered into a strategic partnership with Qubiotech Health Intelligence, S.L., a Spanish developer of the neuroCloud brain PET platform. This move aims to create an independent software platform for quantitative PET imaging, covering both oncology and neurology.
The acquisition of a majority stake in Qubiotech by Claritas will unite Claritas’s cleared PET image enhancement and quantification software with Qubiotech’s neuro-imaging analytics. This combination is expected to provide a comprehensive solution for hospitals and drug developers, offering sharper PET images, automated and reproducible numbers, and compatibility with any scanner.
In oncology, Claritas iPET enhances PET, PET/CT, and PET/MRI images from any radionuclide, with validation across Zr-89, Ga-68, and F-18 chemistries. iPETcertum adds FDA-cleared automated segmentation with SUV and volume quantification, ensuring consistent and repeatable measurements. In neurology, neuroCloud delivers fully automated brain PET analysis, including amyloid Centiloid scoring for all three approved amyloid tracers, from the PET scan alone, with no MRI and no hand-drawn regions.
The combined platform will run on-site, on standard DICOM, with no capital outlay and no dependence on a single vendor. This independence is crucial for departments running mixed fleets and drug developers conducting multi-center trials. The partnership also brings a European base to Claritas, with Qubiotech’s research and development center in Galicia, Spain, and a CE-marked neuro platform.
The transaction unites Claritas’s cleared PET image enhancement and quantification software with Qubiotech’s neuro-imaging analytics, creating a single independent software platform for quantitative PET that spans oncology and neurology. This platform is designed to address the growing demand for independent software solutions in nuclear medicine, particularly in the context of theranostics and neurology.
The combined platform is expected to provide hospitals and imaging networks with a single, vendor-neutral supplier for image quality and quantification across oncology, theranostics, and neurology, replacing the current patchwork of tools tied to specific scanner manufacturers. This move is significant as it addresses the need for sharper images and numbers that are automated, reproducible, and consistent across sites, scanners, and tracers.
Both waves of transformation in nuclear medicine, theranostics and neurology, are driving the demand for such a platform. In oncology, PET is used to choose patients for radiopharmaceutical therapy and to track their response. In neurology, amyloid-targeting therapies make brain PET the gateway to treatment and the yardstick for monitoring it. Both applications require sharper images and numbers that are automated, reproducible, and consistent.
The combined company is well-positioned to meet these demands. Claritas iPET enhances PET, PET/CT, and PET/MRI images from any radionuclide, with validation across Zr-89, Ga-68, and F-18 chemistries. iPETcertum adds FDA-cleared automated segmentation with SUV and volume quantification, ensuring consistent and repeatable measurements. NeuroCloud, CE-marked, delivers fully automated brain PET analysis, including amyloid Centiloid scoring for all three approved amyloid tracers, from the PET scan alone, with no MRI and no hand-drawn regions.
The platform runs on-site, on standard DICOM, with no capital outlay and no dependence on a single vendor. This independence is crucial for departments running mixed fleets and drug developers conducting multi-center trials. The combined company is also well-positioned to compete with anyone in quantitative PET, just as amyloid therapies make brain PET indispensable.
The partnership brings a European base to Claritas, with Qubiotech’s research and development center in Galicia, Spain, and a CE-marked neuro platform. This combination is expected to provide a comprehensive solution for hospitals and drug developers, offering sharper images, automated and reproducible numbers, and compatibility with any scanner.